Eutilex Co., Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2
Ending by 2030
Dec 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due May 12, 2027The maintenance fee for HAR-NDS-derived stem cells, method for separating same, and use thereof (US 10,471,097) comes due May 12, 2027. Unpaid by Nov 12, 2027, it lapses early.
- 1 fee due Jul 2, 2027The maintenance fee for Anti-human 4-1BB antibodies and uses thereof (US 11,859,004) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.
- 4 fees due Aug 9 to 25, 2027 · next Aug 9
- 3 fees due Oct 9 to 21, 2027 · next Oct 9
Recent changes
- 1 of the patents on this record was granted since Aug 17, 2026
- 1 term has ended since Aug 17, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,932,045 | Method of isolating and proliferating autologous antigen-specific CD8+ T cell using anti-4-1BB antibodies In force · From the USPTO record | In force | From the USPTO record | |
| US 8,445,643 | Anti-IRC85 monoclonal antibody; and composition comprising the same for preventing and treating tuberculosis or enteritis disease; and the use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,309,321 | Monoclonal antibody specifically recognizing an epitope for switching to Th17 cell In force · From the USPTO record | In force | From the USPTO record | |
| US 9,255,152 | Antibody specifically recognizing an epitope for switching to Th2 cell and a method for converting T cell to type 2 helper T cell using the same In force · From the USPTO record | In force | From the USPTO record | |
| US 9,255,151 | Antibody specifically recognizing an epitope for switching to TH1 cell In force · From the USPTO record | In force | From the USPTO record | |
| US 10,851,151 | Epitope for switching to TH17 cell and use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 10,233,254 | Monoclonal Antibody Which Specifically Recognizes B Cell Lymphoma and Use Thereof In force · Medium confidence | In force | Medium confidence | |
| US 10,570,371 | Methods for isolating and proliferating autologous cancer antigen-specific CD8+T cells In force · From the USPTO record | In force | From the USPTO record | |
| US 10,471,097 | HAR-NDS-derived stem cells, method for separating same, and use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,862,775 | Monoclonal Antibody Which Specifically Recognizes B Cell Lymphoma and Use Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 26: 4 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 5 abandoned · 6 no status recorded